Sabby Management LLC Has Upped Position in Nektar Therapeutics (NKTR) by $4.12 Million as Market Value Declined

June 17, 2018 - By Stephen Andrade

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment increased to 1.43 in 2018 Q1. Its up 0.24, from 1.19 in 2017Q4. It is positive, as 23 investors sold NKTR shares while 97 reduced holdings. 99 funds opened positions while 73 raised stakes. 153.40 million shares or 2.02% more from 150.36 million shares in 2017Q4 were reported. Cibc Asset Management holds 13,334 shares or 0.01% of its portfolio. Mutual Of America Limited Liability Company stated it has 0.16% in Nektar Therapeutics (NASDAQ:NKTR). Prudential reported 0.03% in Nektar Therapeutics (NASDAQ:NKTR). Chicago Equity Lc invested 0.2% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Van Eck Assoc has 172,081 shares for 0.09% of their portfolio. Amundi Pioneer Asset Mngmt holds 0.03% in Nektar Therapeutics (NASDAQ:NKTR) or 172,684 shares. Fifth Third Comml Bank holds 60 shares or 0% of its portfolio. Weiss Multi owns 5,000 shares. Systematic Fincl Mgmt Limited Partnership, New Jersey-based fund reported 158,707 shares. Mackay Shields Lc reported 0.04% stake. State Street has invested 0.06% in Nektar Therapeutics (NASDAQ:NKTR). Marshall Wace Llp holds 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 7,291 shares. Westfield Capital Management Company Ltd Partnership reported 0.83% in Nektar Therapeutics (NASDAQ:NKTR). Macquarie invested 0% in Nektar Therapeutics (NASDAQ:NKTR). First Trust LP owns 731,882 shares.

Since January 2, 2018, it had 1 buy, and 34 selling transactions for $90.80 million activity. GREER R SCOTT sold $2.77 million worth of stock. Nicholson John also sold $410,029 worth of Nektar Therapeutics (NASDAQ:NKTR) shares. Thomsen Jillian B. sold $298,203 worth of stock. $53,046 worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Hora Maninder. Shares for $1.07M were sold by ROBIN HOWARD W on Wednesday, May 16. Labrucherie Gil M also sold $288,382 worth of Nektar Therapeutics (NASDAQ:NKTR) shares.

Hal Mintz increased its stake in Nektar Therapeutics (NKTR) by 194.16% based on its latest 2018Q1 regulatory filing with the SEC. Sabby Management Llc bought 38,831 shares as the company’s stock declined 11.70% with the market. The hedge fund run by Hal Mintz held 58,831 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $6.25M, up from 20,000 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be bullish on the $9.92B market cap company. The stock increased 2.57% or $1.45 during the last trading session, reaching $57.86. About 4.74M shares traded or 25.45% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 271.91% since June 17, 2017 and is uptrending. It has outperformed by 259.34% the S&P500.

Sabby Management Llc, which manages about $835.79M and $840.84 million US Long portfolio, decreased its stake in Mannkind Corp (Call) by 1.45 million shares to 1,000 shares, valued at $228,000 in 2018Q1, according to the filing. It also reduced its holding in Ishares Russell 2000 (Call) by 1,705 shares in the quarter, leaving it with 2,500 shares, and cut its stake in Inspiremd Inc.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Fool.com which released: “Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today” on June 06, 2018, also Fool.com with their article: “Why Nektar Therapeutics Stock Stumbled 11.8% Today” published on June 08, 2018, Seekingalpha.com published: “Rounds Report: Solid Biosciences Rallied While FDA Approved The First Generic Suboxone” on June 17, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Nasdaq.com and their article: “Why Nektar Therapeutics Shares Are Plunging Today” published on June 04, 2018 as well as Nasdaq.com‘s news article titled: “Why Bristol-Myers Squibb Company Shares Are Down Today” with publication date: June 04, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 8 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Nektar Therapeutics has $125 highest and $54 lowest target. $96.43’s average target is 66.66% above currents $57.86 stock price. Nektar Therapeutics had 14 analyst reports since January 9, 2018 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Neutral” rating given on Monday, June 11 by H.C. Wainwright. The rating was maintained by JP Morgan on Monday, June 4 with “Overweight”. Canaccord Genuity maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Wednesday, January 10. Canaccord Genuity has “Buy” rating and $80.0 target. The firm has “Buy” rating by Canaccord Genuity given on Friday, May 11. The rating was maintained by Cowen & Co with “Buy” on Monday, April 9. The firm earned “Buy” rating on Tuesday, June 5 by Canaccord Genuity. The rating was maintained by PiperJaffray on Friday, April 13 with “Overweight”. The firm has “Buy” rating by Cowen & Co given on Monday, June 4. On Thursday, March 29 the stock rating was maintained by Mizuho with “Buy”. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, April 2.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.